SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

        Date of Report (Date of earliest event reported) April 18, 2000

                                  ENZON, INC.
             (Exact name of registrant as specified in its charter)



          Delaware                      0-12957                  22-237286
(State or other jurisdiction          (Commission              (IRS Employer
      of incorporation)               File Number)            Identification)


                20 Kingsbridge Road, Piscataway, New Jersey 08854
               (Address of principal executive offices) (Zip Code)



       Registrant's telephone number, including area code (732) 980- 4500



- --------------------------------------------------------------------------------
          (Former name or former address, if changed since last report)





Item 5. Other Events

     Enzon,  Inc.  announced  that  results  from a  Phase  III  clinical  trial
comparing  the safety and  efficacy of  PEG-INTRON(TM)  (peginterferon  alfa-2b)
Injection  and  INTRON(R) A  (interferon  alfa-2b,  recombinant)  Injection,  as
monotherapy  for the  treatment  of  hepatitis  C will  be  presented  by  study
investigators  at the upcoming  European  Association for the Study of the Liver
(EASL 2000) annual  meeting on May 1, 2000.  These  results  were  reported in a
study abstract, posted on http://www.easl.com. In this study, after 48- weeks of
treatment plus a 24-week  follow-up  period,  25% of the patients treated with a
once weekly dose of ug/kg of  PEG-INTRON  showed a sustained  viral  response as
compared to 12% of  patients  receiving  INTRON A three times a week.  The trial
also concluded that  PEG-INTRON  was as safe as INTRON A.  Preliminary  Phase II
clinical  results of  PEG-Intron  and REBETOL  Combination  Therapy will also be
presented by study investigators.

     Schering-Plough Corporation currently markets INTRON A, for hepatitis B and
C  and  various  cancers,  and  REBETRON(TM),  a  combination  of  INTRON  A and
REBETOL(R)  (ribavirin) capsules,  for hepatitis C. Schering-Plough has reported
that the 1999 aggregate  worldwide sales of INTRON A/REBETRON were approximately
$1.1 billion.

     Monotherapy  with  PEG-INTRON  may  provide  an  alternative  treatment  to
hepatitis C patients who currently cannot tolerate REBETRON Combination Therapy.

     Schering-Plough,  in February 2000,  announced that the European Union (EU)
Committee for Proprietary  Medicinal  Products (CPMP) of the European Agency for
the  Evaluation  of Medicinal  Products  (EMEA)  issued an opinion  recommending
approval  of  PEG-INTRON  for  hepatitis  C.  Product  approval  by the  EMEA is
typically  issued  three  months  from the time that the  Committee  renders its
opinion.  Approval of this application for PEG-INTRON will allow Schering-Plough
the  market  PEG-INTRON   throughout  the  European  Union.  In  December  1999,
Schering-Plough  submitted a Biologics License  Application,  or BLA, to the FDA
seeking marketing approval for PEG-INTRON for the treatment of chronic hepatitis
C.

     A complete  copy of the  abstract is available  at  http://www.easl.com  or
http://journals.munksgaard.dk/easl/html/hep717.htm

     Certain statements made herein related to potential  government  approvals,
market potential,  commercialization  and sales revenues of medical products and
biologics,  as  well  as  their  therapeutic   applications  and  outcomes,  are
forward-looking  and are made  pursuant  to the safe  harbor  provisions  of the
Securities  Litigation  Reform Act of 1995.  Such  statements  involve risks and
uncertainties,  which  may  differ  materially  from  those  set  forth in these
statements. In addition, the economic, competitive, governmental,  technological
and other factors  identified in the Company's  filings with the  Securities and
Exchange Commission could affect such results.






                                   SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


Dated: April 19, 2000


                                                  ENZON, INC.
                                                 (Registrant)



                              By:        /s/ KENNETH J. ZUERBLIS
                                        -----------------------------------
                                        Kenneth J. Zuerblis
                                        Vice President,
                                        Finance and Chief Financial Officer